Skip to content
value.today

Surface Pharmaceuticals, Inc.

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2017
Total raised
$40 M
2 rounds on record
Latest round
$25 M
May 2021
First round on record
May 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Surface Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2021$25 MNo. 2$10 to $50 million

Surface Pharmaceuticals, Inc.: Raise no. 2, May 2021

Investors in this round

444 investors had bought by the notice of Aug 13, 2021: 444 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $31 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$1,537,096
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kamran Hosseini · Executive Officer, Director
  • Perry Andy Sternberg · Executive Officer, Director
  • Adrienne Andy Graves · Director
  • J. Andy Corley · Director
  • Mark Baum · Director
  • Richard Lindstrom · Director
  • Shelley Andy Thunen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Newbridge Securities Corporation (CRD 104065) · broker-dealer Newbridge Securities Corporation (CRD 104065) · Boca Raton, FloridaSold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IL, IN, MA, MD, MI, MN, MO, MT, NC, NJ, NY, OH, OK, OR, PA, PR, RI, SC, TN, TX, UT, VA, WA, WI

Remarks in the notice

  • On the amounts: “$24,551,739 new money; $578,101.50 upon exercise of warrants”

Signed by Kamran Hosseini, Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Aug 13, 2021. Read the notice at the SEC.

equity, optionsSEC
May 2018$15 MNo. 1$10 to $50 million

Surface Pharmaceuticals, Inc.: Raise no. 1, May 2018

Investors in this round

1 investor had bought by the notice of May 22, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $20 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kamran Hosseini · Executive Officer, Director
  • Mark Andrew Baum · Executive Officer, Director
  • Adrienne Andrew Graves · Director
  • J. Andrew Corley · Director
  • Louis Andrew Drapeau · Director
  • Richard L. Lindstrom · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kamran Hosseini, Chief Executive Officer. Source: SEC Form D, newest notice filed May 22, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Surface Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2021).

    SEC Form D · Aug 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2021

That is all the official record says: Surface Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Surface Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 444 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Surface Pharmaceuticals, Inc.
NameRoleNamed in
Kamran HosseiniExecutive officerAug 2021
Perry Andy SternbergExecutive officerAug 2021
Mark Andrew BaumExecutive officerMay 2018
Adrienne Andy GravesDirectorAug 2021
J. Andy CorleyDirectorAug 2021
Kamran HosseiniDirectorAug 2021
Mark BaumDirectorAug 2021
Perry Andy SternbergDirectorAug 2021
Richard LindstromDirectorAug 2021
Shelley Andy ThunenDirectorAug 2021
Adrienne Andrew GravesDirectorMay 2018
J. Andrew CorleyDirectorMay 2018
Louis Andrew DrapeauDirectorMay 2018
Mark Andrew BaumDirectorMay 2018
Richard L. LindstromDirectorMay 2018